Cancer (Solid Tumors)Dietary SuppleNCT07670234
Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions
An observational study of Cancer (Solid Tumors) and Interaction Drug Food, run by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) at 1 site in Morocco.
Trial summary
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer (Solid Tumors), Interaction Drug Food
- What is being tested?
- Dietary Supplement Use Assessment
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 1,000 participants
- Where
- 1 siteMorocco
- Study dates
- 1 Jun 2025to 31 Dec 2027
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients diagnosed with cancer and receiving medical anticancer treatment (chemotherapy, hormone therapy, immunotherapy, or targeted therapy) at the study site. Participants will be assessed for dietary supplement use, tolerance, and potential interactions between dietary supplements and anticancer medications.
Who may be able to join
- Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.
- Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).
- Adult patients : >=18
Who cannot join
- Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.
- Failure or refusal to provide written informed consent.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Badiaa Batlamous contact
Morocco1 site, 1 recruiting
- Recruiting
Institut National d'Oncologie
Rabat
Sihame Lkhoyaali, Professor of Medical Oncology, +212 668-270035, slkhoyaali@cm6.ma
About this study
Official title: Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.
The main questions it aims to answer :
Read more
- What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?
- Are there any potential drug interactions between dietary supplements and anticancer medications?
Participants will:
- Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.
- Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).
- Report any perceived adverse effects related to dietary supplement use to assess tolerance.
- Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.
- Conditions
- Cancer (Solid Tumors), Interaction Drug Food
- Being tested
- Dietary Supplement Use Assessment
- Keywords
- dietary supplements, cancer, Anticancer Therapy
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietary Supplement Use AssessmentBehavioural
Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.
| Study group | Role | What they receive |
|---|---|---|
| Cancer Patients Using Dietary Supplements | Not described Receives: Behavioral: Dietary Supplement Use Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of Dietary Supplement Use and Tolerance
Assessment of the prevalence of dietary supplement use among cancer patients and evaluation of adverse effects associated with dietary supplement consumption.
Measured: At enrollment
Potential Drug-Supplement Interactions
Assessment of potential interactions between dietary supplements and anticancer medications
Measured: At enrollment or single study visit
Secondary outcomes (1)
Potential Drug-Supplement Interactions Assessed by Artificial Intelligence
Assessment of potential interactions between dietary supplements and anticancer treatments using Hedrine software.
Measured: At enrollment or Single study visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2026
- Study start1 Jun 2025
- Primary completionJun 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer (Solid Tumors)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sihame Lkhoyaali, Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07670234
- Sponsor's protocol ID
- ONCOSUPP-2026-08
- Other IDs
- CE/UM6SS/18/2025
- Acronym
- Dietary Supple
- Status last verified
- Jun 2026
- First submitted
- 19 Jun 2026
- Last updated
- 26 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Use of Dietary Supplements Among Cancer Patients: Tolerance and Impact on Medications and Drug Interactions Assessed Using the Hedrine Software
- ClinicalTrials.gov ID
- NCT07670234
- Acronym / sponsor ID
- Dietary Supple / ONCOSUPP-2026-08
- Conditions
- Cancer (Solid Tumors), Interaction Drug Food
- Keywords
- dietary supplements, cancer, Anticancer Therapy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)University, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 26 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.
The main questions it aims to answer :
- What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?
- Are there any potential drug interactions between dietary supplements and anticancer medications?
Participants will:
- Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.
- Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).
- Report any perceived adverse effects related to dietary supplement use to assess tolerance.
- Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cancer Patients Using Dietary Supplements | – | Behavioral: Dietary Supplement Use Assessment |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients diagnosed with cancer and receiving medical anticancer treatment (chemotherapy, hormone therapy, immunotherapy, or targeted therapy) at the study site. Participants will be assessed for dietary supplement use, tolerance, and potential interactions between dietary supplements and anticancer medications.
Key inclusion criteria (3 listed)
- Patients diagnosed with cancer and receiving medical anticancer treatment, including chemotherapy, hormone therapy, immunotherapy, and targeted therapies.
- Current or recent use of one or more dietary supplements (e.g., vitamins, minerals, herbal products, or other nutritional supplements).
- Adult patients : >=18
Key exclusion criteria (2 listed)
- Patients unable to complete the study questionnaire because of cognitive impairment or a deteriorated health condition.
- Failure or refusal to provide written informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietary Supplement Use AssessmentParticipants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments. | Behavioural | Cancer Patients Using Dietary Supplements |
Primary outcome
Prevalence of Dietary Supplement Use and Tolerance
Time frame: At enrollment
Assessment of the prevalence of dietary supplement use among cancer patients and evaluation of adverse effects associated with dietary supplement consumption.
Potential Drug-Supplement Interactions
Time frame: At enrollment or single study visit
Assessment of potential interactions between dietary supplements and anticancer medications
1 secondary outcome
Potential Drug-Supplement Interactions Assessed by Artificial Intelligence
Time frame: At enrollment or Single study visit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer (Solid Tumors)
RecruitingPhase 1
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Advanced Solid Tumor
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Recruiting
Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment
Adjustment Disorder, Anxiety Disorder
RecruitingPhase 1
Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors
Advanced Solid Tumors
RecruitingObservational study
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Colorectal Neoplasms, Gastric Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Badiaa Batlamous contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer (Solid Tumors) and Interaction Drug Food, run by Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI) at 1 site in Morocco.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Morocco. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sihame Lkhoyaali, Professor of Medical Oncology (+212 668-270035, slkhoyaali@cm6.ma), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of Dietary Supplement Use and Tolerance (time frame: At enrollment). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026.